Zentalis Pharmaceuticals Inc’s recently made public that its Chief Scientific Officer Lackner Mark unloaded Company’s shares for reported $13762.0 on Jan 02 ’25. In the deal valued at $3.12 per share,4,411 shares were sold. As a result of this transaction, Lackner Mark now holds 191,317 shares worth roughly $0.51 million.
Then, Diana Hausman bought 9,888 shares, generating $28,294 in total proceeds.
Before that, Vultaggio Vincent sold 1,603 shares. Zentalis Pharmaceuticals Inc shares valued at $5,098 were divested by the Principal Accounting Officer at a price of $3.18 per share. As a result of the transaction, Vultaggio Vincent now holds 33,855 shares, worth roughly $89377.2.
Wedbush upgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in mid June from “a Buy” to “a Neutral”. Wells Fargo also remained covering ZNTL and has decreased its forecast on June 18, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating. Wedbush revised its rating on June 18, 2024. It rated ZNTL as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ZNTL
On Tuesday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock jump 3.32% to $2.64. Over the last five days, the stock has lost -15.50%. Zentalis Pharmaceuticals Inc shares have fallen nearly -12.71% since the year began. Nevertheless, the stocks have fallen -80.94% over the past one year. While a 52-week high of $18.07 was reached on 01/03/25, a 52-week low of $2.46 was recorded on 01/14/25. SMA at 50 days reached $3.31, while 200 days put it at $5.92.
Levels Of Support And Resistance For ZNTL Stock
The 24-hour chart illustrates a support level at 2.48, which if violated will result in even more drops to 2.32. On the upside, there is a resistance level at 2.74. A further resistance level may holdings at 2.84. The Relative Strength Index (RSI) on the 14-day chart is 37.48, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.33, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.46%. Stochastics %K at 12.91% indicates the stock is a buying.
How much short interest is there in Zentalis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Zentalis Pharmaceuticals Inc stocks on 2024-12-31, dropping by -0.13 million shares to a total of 4.54 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 4.67 million shares. There was a decline of -2.77%, which implies that there is a negative sentiment for the stock.
